1-{3-(5-chlorofuran-2-yl)-2-[2-(1H-imidazol-4-yl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl}-3-[4-(methylsulfanyl)phenyl]urea | 1393088-54-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 1-{3-(5-chlorofuran-2-yl)-2-[2-(1H-imidazol-4-yl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl}-3-[4-(methylsulfanyl)phenyl]urea
• 英文别名: 1-[3-(5-chlorofuran-2-yl)-2-[2-(1H-imidazol-5-yl)ethyl]-1-oxo-3,4-dihydroisoquinolin-7-yl]-3-(4-methylsulfanylphenyl)urea
• CAS: 1393088-54-4
• 化学式: C₂₆H₂₄ClN₅O₃S
• 分子量: 522.027
• InChiKey: QJAXZYQIBNVONT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  129
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Novel 1-(1-OXO-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)Urea Derivatives As N-FORMYL Peptide Receptor Like-1 (FPRL-1) Receptor Modulators
  申请人：Beard Richard L.

  公开号：US20120208842A1

  公开（公告）日：2012-08-16

  The present invention relates to novel 1-(1-Oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

  本发明涉及新颖的1-(1-氧代-1,2,3,4-四氢异喹啉-7-基)脲衍生物，其制备方法，含有它们的药物组合物以及它们作为药物的用途，用作N-甲酰肽受体类似物-1（FPRL-1）受体的调节剂。
• Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
  申请人：Allergan, Inc.

  公开号：US10208071B2

  公开（公告）日：2019-02-19

  The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

  本发明涉及一种在需要治疗的受试者中治疗眼部炎症疾病的方法，该方法包括施用一种药物组合物，该药物组合物包含治疗有效量的至少一种甲酰肽受体 2 的激动剂。
• Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
  申请人：Allergan, Inc.

  公开号：US10434112B2

  公开（公告）日：2019-10-08

  The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

  本发明涉及一种通过局部或全身给药治疗需要此类治疗的受试者的皮肤炎症和皮肤疾病的方法，该方法包括给药一种药物组合物，该药物组合物包含治疗有效量的至少一种甲酰肽受体 2（FPR2）激动剂。
• NOVEL 1-(1-OXO-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS
  申请人：Allergan, Inc.

  公开号：EP2673263A1

  公开（公告）日：2013-12-18
• USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES
  申请人：ALLERGAN, INC.

  公开号：EP2964213B1

  公开（公告）日：2020-11-04